Skip to content

The study of assessing endometrial receptivity and predicting pregnancy outcome in patients with recurrent miscarriage and repeated implant failure by using optical coherence tomography (OCT) .

The study of assessing endometrial receptivity and predicting pregnancy outcome in patients with recurrent miscarriage and repeated implant failure by using optical coherence tomography (OCT) .

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039374
Enrollment
Unknown
Registered
2020-10-25
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent miscarriages and failed repeated implantation

Interventions

Gold Standard:Clinical outcome
(OCT)

Sponsors

Shenzhen Maternity and Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
28 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged < 40 years; 2. Subjects with regular menstruation (28-40 days); 3. Subjects with normal basal endocrine level (FSH < 10iu / L, LH < 10iu / L, E2 < 50pg / ml); 4. Subjects of repeated abortion and repeated planting failure.

Exclusion criteria

Exclusion criteria: 1. Patients with suspected pelvic infection or recent history of pelvic infection (within 4 weeks); 2. Clinical investigation showed one or more of the following positive results: abnormal chromosome analysis of parents, abnormal immune indexes such as anticardiolipin antibody and lupus anticoagulant, abnormal endocrine indexes such as thyroid function, and abnormal ultrasound examination; 3. Patients with endometriosis, adenomyosis, uterine malformation, intrauterine adhesions, submucous myoma, uterine polyps and other abnormal uterine changes detected by endoscopy; 4. Patients with systemic diseases that may cause abnormal fertility, such as diabetes or systemic lupus erythematosus, etc; 5. Patients with previous hyperprolactinemia (hPRL), history of hypothalamic and pituitary diseases, abnormal morphology or function of adrenal cortex and thyroid, and previous tumor; 6. Women with IUD; 7. Patients who had taken immunomodulatory drugs, hormonal drugs and cytotoxic drugs 3 months before treatment.

Design outcomes

Primary

MeasureTime frame
endometrial receptivity;rate of pregnancy;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactLiu Qingzhi

Shenzhen Maternal and Child Health Hospital

liuqingzhi1002@126.com+86 13825266991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026